BioAsia 2026 positions Telangana as a global TechBio powerhouse
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Subscribe To Our Newsletter & Stay Updated